|
Oct 7
|
Palatin Receives Notice of Non-Compliance from NYSE American
|
|
Oct 2
|
Q4 2024 Palatin Technologies Inc Earnings Call
|
|
Oct 2
|
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...
|
|
Oct 1
|
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
|
|
Jun 21
|
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
|
|
Jun 21
|
Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
|
|
Jun 13
|
Palatin Technologies commences Phase II study of obesity treatment
|
|
Jun 12
|
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
|
|
May 16
|
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 16
|
Q3 2024 Palatin Technologies Inc Earnings Call
|
|
May 15
|
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
|
|
May 9
|
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
|
|
May 2
|
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
|
|
Apr 30
|
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
|
|
Apr 14
|
10 Micro-Cap Healthcare Stocks Insiders Are Buying
|
|
Apr 9
|
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
|
|
Apr 8
|
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
|
|
Apr 8
|
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
|
|
Dec 20
|
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
|
|
Dec 18
|
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
|